UA91000C2 - 2,4-pyrimidinediamine compounds anduse thereof - Google Patents
2,4-pyrimidinediamine compounds anduse thereofInfo
- Publication number
- UA91000C2 UA91000C2 UAA200602138A UAA200602138A UA91000C2 UA 91000 C2 UA91000 C2 UA 91000C2 UA A200602138 A UAA200602138 A UA A200602138A UA A200602138 A UAA200602138 A UA A200602138A UA 91000 C2 UA91000 C2 UA 91000C2
- Authority
- UA
- Ukraine
- Prior art keywords
- anduse
- pyrimidinediamine compounds
- symptoms
- treating
- preventing
- Prior art date
Links
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49164103P | 2003-07-30 | 2003-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA91000C2 true UA91000C2 (en) | 2010-06-25 |
Family
ID=50687771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200602138A UA91000C2 (en) | 2003-07-30 | 2004-07-30 | 2,4-pyrimidinediamine compounds anduse thereof |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA91000C2 (en) |
-
2004
- 2004-07-30 UA UAA200602138A patent/UA91000C2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG145698A1 (en) | Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds | |
| PL373455A1 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
| SI1814878T1 (en) | Spiro-2, 4-pyrimidinediamine compounds and their uses | |
| BG108857A (en) | Glutaminyl based dpiv inhibitors | |
| MY139142A (en) | Short corridor progressive addition lenses with reduced unwanted astigmatism | |
| SI2270048T1 (en) | Anti-NGF antibodies and methods using same | |
| WO2005039504A3 (en) | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | |
| BR9915604A (en) | Tgfbeta1 inhibitory peptides | |
| WO2003084560A3 (en) | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis | |
| BR9808606A (en) | Materials and methods for treating diseases with ribozymes | |
| WO2004100890A3 (en) | Rage g82s-related methods and compositions for treating inflammatory disorders | |
| MY135829A (en) | Analeptic and drug combinations | |
| AU1171102A (en) | Uridine therapy for patients with elevated purine levels | |
| UA91000C2 (en) | 2,4-pyrimidinediamine compounds anduse thereof | |
| EP2130541A3 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
| EP1199372A3 (en) | Polymorphisms in the human P2X7 gene | |
| WO2003013436A3 (en) | Kavalactone compositions and methods of use | |
| WO2003064394A8 (en) | 5-ring heterocycles used as antiviral agents | |
| DE602004012759D1 (en) | TREATMENT OF FIBROSES | |
| EP1184465A3 (en) | Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms | |
| WO2002078698A3 (en) | Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine | |
| CO5040128A1 (en) | FAS COMBINED BLENDS |